Annual Securities Report — FY2025
What ROHTO PHARMACEUTICAL CO.,LTD. reported for the period from 2025-04-01 to 2026-03-31.
Filed 2026-06-19View the original on EDINET
How much it says
65Detailed
What moved here
20named for the first time
Its own wording
62terms
Which filing this is
33/ 33newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the period, consolidated revenue increased, as did operating profit, ordinary profit and profit attributable to owners of the parent. Disclosures regarding policies and organizational structures related to sustainability, R&D and governance have also continued.
Komori's summary of this document, not the document's own words.65Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 37 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
100
Very detailed
97
Very detailed
38
Thin
0
Almost nothing
100
Very detailed
0
Almost nothing
73
Detailed
100
Very detailed
60
Detailed
55
Typical
50
Typical
R&D spend139億円Money spent making new things.
Cash left over-414億円Cash from the business, less what went into equipment.
Spent on equipment150億円Plants, machines — things meant to last.
Employees9,292Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.